Naloxone reversed suspected synthetic cannabinoid overdose despite negative opioid tests

A 43-year-old man with schizoaffective disorder presented with altered mental status and respiratory depression after suspected K2 use. He improved with intranasal naloxone despite negative opioid and synthetic cannabinoid screens. He later admitted ongoing K2 use. The clinical response suggests either opioid adulteration of the K2 or functional interactions between CB1 and opioid receptors.

Case report with literature review. Standard toxicology screens for opioids and known synthetic cannabinoids were negative. Clinical response to naloxone was documented across episodes. A unit search found leafy substances, but confirmatory testing was negative due to the constantly changing chemical composition of synthetic cannabinoids.

Synthetic cannabinoid products are increasingly contaminated with opioids, and standard toxicology screens cannot detect most novel synthetic cannabinoids. This case demonstrates that naloxone should be considered in undifferentiated overdoses even without confirmed opioid exposure, given its safety profile and potential effectiveness.

The inability of standard tests to detect novel synthetic cannabinoids is a growing crisis. The street drug supply is increasingly contaminated with fentanyl and other opioids, meaning that what users think is a cannabinoid product may contain lethal opioid doses. Naloxone's safety makes it a reasonable intervention even when the diagnosis is uncertain.

Single case report cannot establish causation. The mechanism (opioid contamination vs CB1-opioid crosstalk) remains uncertain. Negative toxicology could mean either no opioids were present or the specific opioid was undetectable by standard screens. Concurrent medications and schizoaffective disorder complicate interpretation.